Italia markets close in 4 hours 34 minutes

FTSE MIB
34.895,18
-503,64(-1,42%)
Dow Jones
40.003,59
+134,19(+0,34%)
Nasdaq
16.685,97
-12,33(-0,07%)
Nikkei 225
39.069,68
+282,30(+0,73%)
Petrolio
79,89
-0,17(-0,21%)
Bitcoin EUR
61.771,86
-213,54(-0,34%)

NBIX Aug 2024 130.000 call

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

16,89

0,00

(0,00%)

In data: 03:52PM EDT. Mercato aperto.

GlobeNewswire
Sosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditionsNBI-1117570 is the second compound to advance into clinical development from a portfolio of selective muscarinic receptor agonists licensed by Sosei Heptares to Neurocrine following NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is in Phase 2 clinical trials as an investigational treat